Palisade Bio (PALI) Asset Utilization Ratio (2012 - 2026)

Palisade Bio (PALI) posted quarterly Asset Utilization Ratio of 0.02 for Q4 2023, up 13.62% quarter-over-quarter from 0.01 in Q3 2023.

Palisade Bio (PALI) Asset Utilization Ratio (2012 - 2026) Analysis & Trends

Palisade Bio (PALI) has reported Asset Utilization Ratio for 11 consecutive years, with 0.02 the latest figure, recorded in Q4 2023.

In Q4 2023, Asset Utilization Ratio changed N/A year-over-year to 0.02; the TTM figure through Dec 2023 stood at 0.02 (changed N/A YoY), while the FY2023 annual figure was 0.02, changed N/A from the prior year.
Asset Utilization Ratio grew to 0.02 in Q4 2023 per PALI's latest filing, from 0.01 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.04 in Q1 2019 and bottomed at 0.0 in Q3 2022.
Historically, Asset Utilization Ratio has averaged 0.01 across 4 years, with a median of 0.0 in 2020.
Annual changes were most pronounced in 2019 — Asset Utilization Ratio sank 95.89% — and 2023, when it soared 6708.27%.
Palisade Bio's Asset Utilization Ratio stood at 0.0 in 2019, then dropped by 25.02% to 0.0 in 2020, then plunged by 86.03% to 0.0 in 2022, then soared by 7635.47% to 0.02 in 2023.
Business Quant data shows PALI's Asset Utilization Ratio at 0.02 in Q4 2023, 0.01 in Q3 2023, and 0.01 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.38
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.69
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	186.67
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.13
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.90
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.54
10	Palisade Bio	372.94 Mn	247.74 Mn	-	0.00

Download Data